Opendata, web and dolomites

HAP2 SIGNED

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 HAP2 project word cloud

Explore the words cloud of the HAP2 project. It provides you a very rough idea of what is the project "HAP2" about.

academia    infections    placed    ifn    il    incidence    500    treatment    prevention    breaking    hap    precision    integrative    respiratory    first    gamma    interdisciplinary    frequent    complete    drugs    biological    stratified    pneumonia    medicine    clinical    risk    altering    sciences    dysbiosis    clinico    alternative    directed    capitalising    resistant    uniquely    predict    expertise    genetic    12    revolutionize    social    supplementation    variation    immunosuppression    30    diseases    recommendations    hospitals    strategies    biomarkers    axis    patients    pathogens    score    microbiome    cure    therapies    medical    resistance    physiopathology    pathogen    fight    industry    trials    illness    preventive    antibiotic    bacterial    reappraisal    acquired    episodes    omics    outcome    severe    hap2    infectious    disease    consumption    ground    infection    critical    survival    world    host    ambition    course    immunology    dramatic    despite    interactions    hospital    defective    urgently    drug   

Project "HAP2" data sheet

The following table provides information about the project.

Coordinator
CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES 

Organization address
address: Allee de l'Ile Gloriette 5
city: NANTES
postcode: 44093
website: www.chu-nantes.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 9˙996˙350 €
 EC max contribution 9˙996˙350 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2019-Two-Stage-RTD
 Funding Scheme RIA
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2024-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES FR (NANTES) coordinator 3˙642˙770.00
2    UNIVERSITAT ZURICH CH (ZURICH) participant 1˙510˙587.00
3    UNIVERSITE DE NANTES FR (NANTES CEDEX 1) participant 1˙273˙025.00
4    FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA ES (BARCELONA) participant 841˙365.00
5    STICHTING KATHOLIEKE UNIVERSITEIT NL (NIJMEGEN) participant 785˙000.00
6    NEUMEDICINES INC. US (TUJUNGA CA) participant 732˙127.00
7    BIG DATA SANTE FR (NANTES) participant 477˙328.00
8    UNIVERSITY OF MICHIGAN THE REGENTS OF THE UNIVERSITY OF MICHIGAN US (ANN ARBOR) participant 322˙837.00
9    HOSPICES CIVILS DE LYON FR (LYON) participant 315˙227.00
10    ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON EL (ATHINA) participant 96˙081.00

Map

 Project objective

“HAP2” aims to develop stratified host-directed drugs and biomarkers to enhance the prevention and the treatment of hospital-acquired pneumonia (HAP) and develop precision medicine in infectious diseases. HAP is an infectious disease of major concern in the world, and the most frequent cause of hospital-acquired infections with 500,000 episodes being treated every year in Europe. Despite the development of European recommendations, the incidence remains high, with dramatic medical consequences: existing therapies and preventive measures do not result in the expected favourable outcome (clinical cure and survival) for 30% of patients. HAP are moreover the main cause of antibiotic consumption in European hospitals and are increasingly induced by drug-resistant pathogens. New, alternative and more effective host-targeted strategies are therefore urgently needed to fight antibiotic resistance. The ambition of “HAP2” is to revolutionize the management of HAP: capitalising on the novel concept of critical-illness related immunosuppression altering the host-pathogens interactions, we propose a complete reappraisal of the physiopathology of HAP based on the concept of respiratory dysbiosis. “The HAP2” project will reach two ground-breaking objectives in the field of bacterial infections: first the development of host-targeted approaches for the prevention and the treatment of a severe bacterial infection through the supplementation of the IL-12/IFN-γ axis which is defective in patients at risk of pneumonia; second the development of a clinico-biological score based on an integrative assessment of the host-pathogen interactions and genetic variation, to predict the course of HAP and the response to treatment. Our interdisciplinary consortium, bringing together 10 partners from academia and industry with expertise in clinical trials, immunology, microbiome analysis, omics and social sciences is uniquely placed to achieve this ambition within this 5-year project.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HAP2" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HAP2" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

CLOSER (2019)

Childhood Leukemia: Overcoming distance between South America and Europe Regions

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More